NexgenRx Extends Debenture Maturity Date

NEXGENRX INC. (TSX VENTURE:NXG) ("NexgenRx" or the "Corporation") announces that
it has agreed to further extend the maturity date of its currently outstanding
convertible debenture (the "Debenture"). The Debenture was issued in April 2012
in the principal amount of $500,000 and was set to expire on November 26, 2013.
The Debenture was recently amended to extend the maturity date to December 12,
2013 and to amend the conversion price from $0.30 to $0.20 per common share. The
maturity date has been further extended to June 12, 2015. The TSX Venture
Exchange has approved this amendment to the terms of the Debenture.


About NexgenRx 

NexgenRx is a growing health benefits management company engaged in the design,
management and administration of health benefit plans offered by employers and
other plan sponsors for the benefit of their employees and plan members. More
information on NexgenRx can be found at www.nexgenrx.com.


Caution Regarding Forward-Looking Statements - This news release contains
certain forward looking statements, including statements regarding the business
and anticipated financial performance of the Corporation. These statements are
subject to a number of risks and uncertainties. Actual results may differ
materially from results contemplated by the forward-looking statements. When
relying on forward-looking statements to make decisions, investors and others
should carefully consider the foregoing factors and other uncertainties and
should not place undue reliance on such forward-looking statements.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of the release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Ronald C. Loucks
NexgenRx Inc.
President and CEO
416.695.3393 x801


Taba Merrikh
NexgenRx Inc.
Director of Finance
416-695-3393x803